Detalhe da pesquisa
1.
Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α.
Immunity
; 42(3): 484-98, 2015 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25746953
2.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
3.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28885881
4.
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
J Transl Med
; 17(1): 429, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31878938
5.
NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction.
J Biol Chem
; 292(19): 7866-7887, 2017 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28330872
6.
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Invest New Drugs
; 32(2): 340-6, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24242862
7.
Hypoxia: jump-starting inflammation.
Blood
; 117(9): 2561-2, 2011 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21372159
8.
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.
Cancer Res Commun
; 2(1): 39-48, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860696
9.
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Adv Ther
; 38(6): 2759-2778, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881745
10.
Regulation of the chemokine receptor CXCR4 by hypoxia.
J Exp Med
; 198(9): 1391-402, 2003 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-14597738
11.
Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.
Exp Cell Res
; 315(11): 1850-9, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19362550
12.
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
Drug Resist Updat
; 12(3): 74-80, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19394890
13.
Development of HIF-1 inhibitors for cancer therapy.
J Cell Mol Med
; 13(9A): 2780-6, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19674190
14.
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
J Nat Prod
; 72(5): 805-12, 2009 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19405508
15.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
JAMA Oncol
; 5(2): 195-203, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383184
16.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Eur J Cancer
; 107: 142-152, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30576970
17.
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Clin Cancer Res
; 13(3): 1010-8, 2007 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17289897
18.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clin Cancer Res
; 13(18 Pt 1): 5411-7, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17875771
19.
Meeting report: exploiting the tumor microenvironment for therapeutics.
Cancer Res
; 66(9): 4558-60, 2006 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16651404
20.
Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Mol Cancer Res
; 4(9): 601-5, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16940159